Latest California Healthline Stories
In Rural America, Deadly Costs of Opioids Outweigh the Dollars Tagged to Address Them
Some people say it’s reasonable for densely populated areas to receive more settlement funds, since they serve more of those affected. But others worry this overlooks rural communities disproportionately harmed by opioid addiction.
KHN’s ‘What the Health?’: Congress Races the Clock
Sen. Raphael Warnock’s re-election in Georgia will give Democrats a clear-cut Senate majority for the first time in nearly a decade. Meanwhile, the current Congress has only days left to tackle major unfinished business on the health agenda, including fending off scheduled pay cuts for doctors and other health providers in the Medicare program. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Anna Edney of Bloomberg News, and Sandhya Raman of CQ Roll Call join KHN’s Julie Rovner to discuss these topics and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
Paxlovid Has Been Free So Far. Next Year, Sticker Shock Awaits.
The government soon will stop paying for the covid drug that has proved to be the most effective at keeping patients alive and out of the hospital.
Employers Use Patient Assistance Programs to Offset Their Own Costs
Some insurers and employers are tapping into assistance programs meant for individual patients. The concern: Some costly drugs could be harder for patients to access.
The Business of Clinical Trials Is Booming. Private Equity Has Taken Notice.
Private equity-backed Headlands Research heralded its covid-19 vaccine trials as a chance to boost participation among diverse populations, then it shuttered multiple sites that conducted them.
Para lanzar un nuevo fármaco al mercado, la Administración de Alimentos y Medicamentos (FDA) exige a las farmacéuticas estudios exhaustivos para demostrar su seguridad y eficacia. Conseguir que un medicamento salga al mercado unos meses antes, y con menos gastos de lo habitual, puede traducirse en beneficios millonarios para el fabricante.
KHN’s ‘What the Health?’: Medicaid Machinations
The lame-duck Congress has returned to Washington with a long health care to-do list and only a little time. Meanwhile, some of the states that have not yet expanded Medicaid eligibility under the Affordable Care Act are rethinking those decisions. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these topics and more. Also this week, Rovner interviews KHN’s Fred Clasen-Kelly, who reported and wrote the latest KHN-NPR “Bill of the Month” feature, about a mysterious mishap during minor surgery.
Readers and Tweeters Decry Medical Billing Errors, Price-Gouging, and Barriers to Benefits
KHN gives readers a chance to comment on a recent batch of stories.
Schools, Sheriffs, and Syringes: State Plans Vary for Spending $26B in Opioid Settlement Funds
The cash represents an unprecedented opportunity to derail the opioid epidemic, but with countless groups advocating for their share of the pie, the impact could depend heavily on geography and politics.
Defense Department Health Plan Cuts Its Pharmacy Network by Nearly 15,000 Outlets
Many of the pharmacies were small, independent operations that had decided not to participate next year because of the lowered reimbursement being offered. But they were surprised by an early dismissal, and some patients with specialized drug needs could face difficulties in the transition.